Form 8-K

8-K — Option Care Health, Inc.

Accession: 0001104659-26-052099

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0001014739

SIC: 8082 (SERVICES-HOME HEALTH CARE SERVICES)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2613077d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2613077d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2613077d1_ex99-2.htm)

GRAPHIC (tm2613077d1_8kimg001.jpg)

GRAPHIC (tm2613077d1_ex99-1img001.jpg)

GRAPHIC (tm2613077d1_ex99-2img001.jpg)

GRAPHIC (tm2613077d1_ex99-2img002.jpg)

GRAPHIC (tm2613077d1_ex99-2img003.jpg)

GRAPHIC (tm2613077d1_ex99-2img004.jpg)

GRAPHIC (tm2613077d1_ex99-2img005.jpg)

GRAPHIC (tm2613077d1_ex99-2img006.jpg)

GRAPHIC (tm2613077d1_ex99-2img007.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613077d1_8k.htm · Sequence: 1

false

0001014739

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported)

April 30, 2026

OPTION

CARE HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-11993

05-0489664

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS

Employer Identification Number)

3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015

(Address

of principal executive offices)

(312) 940-2443

(Registrant's

telephone number, including area code)

Check the appropriate box below if the

Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions:

¨ Written communications pursuant to Rule 425 under

the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under

the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period

for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. ¨

Securities registered pursuant to Section 12(b) of

the Act:

Title of each Class

Trading Symbol(s)

Name of each exchange on which registered

Common

Stock, $0.0001 par value per share

OPCH

Nasdaq Global Select Market

Item 2.02. Results of Operations and Financial Condition.

On April 30, 2026, Option Care Health, Inc. (the “Company”)

issued a press release reporting its first quarter 2026 financial results. A copy of the press release is furnished with this Form 8-K

and attached hereto as Exhibit 99.1.

The press release and presentation include certain

non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly

comparable GAAP financial measures is also provided.

Item 7.01. Regulation FD Disclosure.

To supplement the information in the attached

press release, the Company has also prepared a presentation, which will be available on the Company’s website at https://investors.optioncarehealth.com/events-and-presentations/presentations

and is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Form 8-K and the

Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated

by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference

in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press release dated April 30,

2026

99.2

Option Care Health Presentation

dated April 30, 2026

104

Cover Page Interactive

Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Option Care Health, Inc.

Date: April 30,

2026

By:

/s/ Meenal Sethna

Meenal Sethna

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613077d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER

ENDED MARCH 31, 2026

BANNOCKBURN, IL., April 30, 2026 - Option Care Health, Inc.

(the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home

and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

(year-over-year comparisons unless otherwise noted)

· Net revenue of $1,350.7 million,

up 1.3%

· GAAP Net income of $45.3 million,

down 3.0%

· GAAP diluted earnings per share of

$0.29, up 3.6%

· Adjusted EBITDA of $104.8 million,

down 6.3%

· Adjusted diluted earnings per share

of $0.40, flat to the first quarter of 2025

· Cash used in operating activities

of $12.1 million

· Repurchased $17.5 million of stock

in the quarter

· Revolving credit facility expanded

from $400 million to $850 million

“The first quarter reflected a mixed performance for our business,

and we are not satisfied with our revenue growth momentum,” commented John C. Rademacher, President & Chief Executive

Officer, Option Care Health. “Our team continues to provide high-quality care for patients and deepen relationships with key stakeholders

and our foundation remains strong. We are an execution-driven organization and are taking decisive actions to re-accelerate our growth

trajectory and position us for greater long-term value creation.”

Updated Full Year 2026 Financial Guidance

For the full year 2026, Option Care Health now expects to generate:

· Net revenue of $5.675 billion to

$5.775 billion

· Adjusted diluted earnings per share

of $1.82 to $1.92

· Adjusted EBITDA of $480 million to

$505 million

· Cash provided by operating activities

of at least $320 million

Conference Call

Option Care Health will host a conference call to discuss its results

on Thursday, April 30, 2026, at 8:30 a.m. ET. The conference call can be accessed via a live audio webcast that will be available

online at investors.optioncarehealth.com. A replay of the call will be available at the same web link for 90 days after the call.

About Option Care Health

Option Care Health is the nation’s largest independent provider

of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately

to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise

and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn

more, please visit our website at optioncarehealth.com.

Investor Contact

Nicole Maggio

Senior Vice President, Corporate Controller

investor.relations@optioncare.com

Forward-Looking Statements - Safe Harbor

This press release contains “forward-looking statements”

within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements

can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,”

“estimate,” “expect,” “may,” “should,” “will” and similar references to future

periods. Examples of forward-looking statements include, among others, statements the Company may make regarding future revenues, future

earnings, other future financial results, regulatory developments, market developments, new products and growth strategies and the effects

of any of the foregoing on its future results of operations or financial condition.

Forward-looking statements are neither historical facts nor assurances

of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future

of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because

forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that

are difficult to predict and many of which are outside of the Company's control. The Company's actual results and financial condition

may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual

results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the

following: changes in laws, regulations or trade policies applicable to its business model; loss of relationships with managed care organizations

and other non-governmental third party payers; changes in the pharmaceutical industry, including limiting or discontinuing research,

development, production and marketing of pharmaceuticals compatible with its services; changes in market conditions and receptivity to

its services and offerings; and pending and future litigation or potential liability for claims not covered by insurance. For a detailed

discussion of the risk factors that could affect its actual results, please refer to the risk factors identified in the Company's SEC

reports as filed with the SEC.

Any forward-looking statement made by the Company

in this press release is based only on information currently available to it and speaks only as of the date on which it is made. The

Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time

to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with

generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted

earnings per share ("EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial

performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, EPS, or any other performance

measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the

Company’s liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted diluted EPS may

not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted

net income represents net income before intangible asset amortization expense, stock-based compensation expense, loss on extinguishment

of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments, (ii) Adjusted EBITDA represents

net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on

extinguishment of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted diluted EPS represents

Adjusted net income divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration

and other expenses, the Company may incur significant charges such as the write down of certain long-lived assets, temporary redundant

expenses, professional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance

costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that these

adjusted measures provide useful supplemental information regarding the performance of Option Care Health’s business operations

and facilitate comparisons to the Company’s historical operating results. The Company has not reconciled Adjusted EBITDA guidance

to net income or Adjusted diluted EPS guidance to GAAP diluted EPS as management believes creation of this reconciliation would not be

practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each

historical adjusted measure to the most comparable GAAP financial measure are set forth below.

Schedule 1

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)(UNAUDITED)

March 31, 2026

December 31, 2025

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$ 177,321

$ 232,624

Accounts receivable, net

516,436

473,566

Inventories

415,686

471,149

Prepaid expenses and other current assets

85,664

87,629

Total current assets

1,195,107

1,264,968

NONCURRENT ASSETS:

Property and equipment, net

139,939

139,236

Intangible assets, net

21,063

21,897

Referral sources, net

278,845

287,281

Goodwill

1,606,743

Other noncurrent assets

138,403

135,644

Total noncurrent assets

2,184,993

2,190,801

TOTAL ASSETS

$ 3,380,100

$ 3,455,769

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Accounts payable

$ 545,016

$ 639,829

Other current liabilities

184,729

189,519

Total current liabilities

729,745

829,348

NONCURRENT LIABILITIES:

Long-term debt, net of discount, deferred financing costs and current portion

1,153,040

1,154,052

Other noncurrent liabilities

146,246

145,976

Total noncurrent liabilities

1,299,286

1,300,028

Total liabilities

2,029,031

2,129,376

STOCKHOLDERS’ EQUITY

1,351,069

1,326,393

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$ 3,380,100

$ 3,455,769

Schedule

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF EARNINGS

(IN

THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

Three Months

Ended March 31,

2026

2025

NET REVENUE

$ 1,350,654

$ 1,332,972

COST OF REVENUE

1,088,640

1,069,920

GROSS PROFIT

262,014

263,052

OPERATING COSTS AND EXPENSES:

Selling, general and administrative expenses

169,955

162,808

Restructuring, acquisition and integration costs

4,607

5,310

Depreciation and amortization expense

14,907

15,746

Total operating expenses

189,469

183,864

OPERATING INCOME

72,545

79,188

OTHER INCOME (EXPENSE):

Interest expense, net

(13,304 )

(13,231 )

Other, net

1,762

(2,401 )

Total other (expense) income

(11,542 )

(15,632 )

INCOME BEFORE INCOME TAXES

61,003

63,556

INCOME TAX EXPENSE

15,660

16,814

NET INCOME

$ 45,343

$ 46,742

Earnings per share, basic

$ 0.29

$ 0.28

Earnings per share, diluted

$ 0.29

$ 0.28

Weighted average common shares outstanding, basic

156,653

165,460

Weighted average common shares outstanding, diluted

158,209

166,804

Schedule 3

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)(UNAUDITED)

Three Months

Ended March 31,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$ 45,343

$ 46,742

Adjustments to reconcile net income to net cash used in operating activities:

Depreciation and amortization expense

15,655

16,373

Other adjustments

16,625

17,642

Changes in operating assets and liabilities:

Accounts receivable, net

(42,870 )

(56,788 )

Inventories

55,463

21,790

Prepaid expenses and other current assets

1,233

28,444

Accounts payable

(93,246 )

(88,101 )

Accrued compensation and employee benefits

(20,982 )

(14,458 )

Other

10,669

21,142

Net cash used in operating activities

(12,110 )

(7,214 )

CASH FLOWS FROM INVESTING ACTIVITIES:

Acquisition of property and equipment

(9,046 )

(9,371 )

Business acquisitions, net of cash acquired

—

(117,322 )

Other investing activities

(274 )

—

Net cash used in investing activities

(9,320 )

(126,693 )

CASH FLOWS FROM FINANCING ACTIVITIES:

Purchase of company stock and related excise taxes

(17,539 )

(100,222 )

Other financing activities

(16,334 )

(7,064 )

Net cash used in financing activities

(33,873 )

(107,286 )

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

(55,303 )

(241,193 )

Cash and cash equivalents - beginning of period

232,624

412,565

CASH AND CASH EQUIVALENTS - END OF PERIOD

$ 177,321

$ 171,372

Schedule

OPTION CARE HEALTH, INC.

QUARTERLY RECONCILIATION

BETWEEN GAAP AND NON-GAAP MEASURES

(IN THOUSANDS, EXCEPT

PER SHARE AMOUNTS)(UNAUDITED)

Three Months

Ended March 31,

2026

2025

Net income

$ 45,343

$ 46,742

Interest expense, net

13,304

13,231

Income tax expense

15,660

16,814

Depreciation and amortization expense

15,655

16,373

EBITDA

89,962

93,160

EBITDA adjustments

Stock-based incentive compensation expense

10,199

8,801

Restructuring, acquisition, integration and other (1)

4,609

9,806

Adjusted EBITDA

$ 104,770

$ 111,767

Net income

$ 45,343

$ 46,742

Intangible asset amortization expense

9,270

9,097

Stock-based incentive compensation expense

10,199

8,801

Restructuring, acquisition, integration and other (1)

4,609

9,806

Total pre-tax adjustments

24,078

27,704

Tax adjustments (2)

(6,188 )

(7,342 )

Adjusted net income

$ 63,233

$ 67,104

Earnings per share, diluted

$ 0.29

$ 0.28

Adjusted earnings per share, diluted

$ 0.40

Weighted average common shares outstanding, diluted

158,209

166,804

(1) Restructuring, acquisition, integration and other includes $4,607 and $5,310 of operating expenses for the three months ended March 31, 2026 and 2025, respectively.

(2) Tax adjustments for the three months ended March 31, 2026 and 2025 includes the estimated income tax effect on non-GAAP adjustments based on the effective tax rate.

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2613077d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

© 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED Disclaimers Forward - Looking Statements This presentation may contain “forward - looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “shoul d,” “will” and similar references to future periods. Examples of forward - looking statements include, among others, statements we may make regarding future revenues, future earnings, other future financial r esu lts, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial conditions. Forward - looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on ou r current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future condition s. Because forward - looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward - looking statements. Importa nt factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: changes in laws, regulations or trade policies applicable to our business model; loss of relationships with managed care organizations and other non - governmental third party payers; changes in the pharmaceutical indus try, including limiting or discontinuing research, development, production and marketing of pharmaceuticals compatible with our services; changes in market conditions and receptivity to our se rvices and offerings; and pending and future litigation or potential liability for claims not covered by insurance. For a detailed discussion of the risk factors that could affect our actual res ult s, please refer to the risk factors identified in our reports as filed with the SEC. Any forward - looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward - looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Non - GAAP Measures In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), we are a lso reporting Adjusted net income, Adjusted EBITDA, and Adjusted diluted earnings per share ("Adjusted diluted EPS"), each of which are non - GAAP financial measures. These adjusted measures are not meas urements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, net profit margin, earnings per share or any other perform anc e measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of our liquidity. In addition, our definitions of Adjusted ne t i ncome, Adjusted EBITDA, and Adjusted diluted EPS may not be comparable to similarly titled non - GAAP financial measures reported by other companies. As defined by us: ( i ) Adjusted net income represents net income before intangible asset amortization expense, stock - based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments; ( ii) Adjusted EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization, stock - based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses ; and (iii) Adjusted diluted EPS represents Adjusted net income divided by weighted average common shares outstanding, diluted. As part o f r estructuring, acquisition, integration and other expenses, we may incur significant charges such as the write down of certain long - lived assets, temporary redundant expenses, pr ofessional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential accelerated payments or termination costs for cert ain of its contractual obligations. Management believes that these adjusted measures provide useful supplemental information regarding the performance of our business operations and facilitate co mparisons to our historical operating results. We have not reconciled Adjusted EBITDA and Adjusted diluted EPS guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each historical adjusted measure to the most comparable G AAP financial measure are set forth at the end of this presentation. 2 Q1 '26 Earnings Call Presentation | April 30, 2026

© 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED o Mixed Q1 results o Strong execution across Acute o Transitional period for Chronic o Continued focus on strategic initiatives o Full - year 2026 guidance o Adjusting Net Revenue guidance and Cash Flow from Operations target o Maintaining Adj. EBITDA and Adj. Diluted EPS guidance o Taking decisive actions to reaccelerate revenue growth trajectory and drive greater long - term value creation Q1 RESULTS & FULL - YEAR 2026 UPDATE Q1 '26 Earnings Call Presentation | April 30, 2026 3

© 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 4 Q1 2026 FINANCIAL PERFORMANCE Growth Highlights vs. PY o Revenue +1% o Acute: High single digit growth o Chronic: Slight decline o IG/neuro portfolio solid growth o Offset by chronic inflammatory portfolio (CID) decline and certain other specialty therapies o EBITDA ( - 6%) o Strong Acute performance and strategic initiatives offset by CID headwind o Adj. Diluted EPS flat o +$0.02 YoY benefit from share repurchases o Q1 Operating Cash Flow ( - $12M) o Consistent with seasonal patterns $105 $112 Adj. EBITDA $ $0.29 $0.28 GAAP Diluted EPS $0.40 $0.40 Adj. Diluted EPS $1,333 $1,351 Q1 - 25 Q1 - 26 Revenue ($ in millions except EPS) Q1 '26 Earnings Call Presentation | April 30, 2026

FY ’26 Guidance Update + Growth vs. PY 1 © 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED 5 Guidance Key Assumptions FULL - YEAR 2026 GUIDANCE & KEY ASSUMPTIONS o FY ’26 o Approx. ( - 600bps) total company Net Revenue growth headwind from CID o Approx. ( - $55M) GP$ headwind from CID, to be realized evenly over the year o Effective tax rate 26% - 28% o Net interest expense $50M - $55M o Q2 ’26 sequential growth assumptions vs. Q1 ’26 o Net Revenue: +Mid - single digits o Adj. EBITDA: +High - single digits o Net Revenue $5.675B to $5.775B, +1% o Adj. Diluted EPS $1.82 to $1.92, +9% o Adj. EBITDA $480M to $505M, +5% o Cash Flow from Operations of at least $320M 1 Growth represents ’26 midpoint of guidance compared to 2025 results Q1 '26 Earnings Call Presentation | April 30, 2026

© 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED Reconciliation to Non - GAAP Measures For historical reconciliations of non - GAAP financial measures, please see our SEC filings and other financial reports, which are available on our website at investors.optioncarehealth.com 7 Q1 '26 Earnings Call Presentation | April 30, 2026

GRAPHIC

Filename: tm2613077d1_8kimg001.jpg · Sequence: 7

Binary file (10586 bytes)

Download tm2613077d1_8kimg001.jpg

GRAPHIC

Filename: tm2613077d1_ex99-1img001.jpg · Sequence: 8

Binary file (4625 bytes)

Download tm2613077d1_ex99-1img001.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img001.jpg · Sequence: 9

Binary file (146479 bytes)

Download tm2613077d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img002.jpg · Sequence: 10

Binary file (340945 bytes)

Download tm2613077d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img003.jpg · Sequence: 11

Binary file (128895 bytes)

Download tm2613077d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img004.jpg · Sequence: 12

Binary file (144380 bytes)

Download tm2613077d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img005.jpg · Sequence: 13

Binary file (161728 bytes)

Download tm2613077d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img006.jpg · Sequence: 14

Binary file (103442 bytes)

Download tm2613077d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2613077d1_ex99-2img007.jpg · Sequence: 15

Binary file (123784 bytes)

Download tm2613077d1_ex99-2img007.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 17

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

001-11993

Entity Registrant Name

OPTION

CARE HEALTH, INC.

Entity Central Index Key

0001014739

Entity Tax Identification Number

05-0489664

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3000 Lakeside Dr. Suite 300N

Entity Address, City or Town

Bannockburn

Entity Address, State or Province

Entity Address, Postal Zip Code

60015

City Area Code

312

Local Phone Number

940-2443

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value per share

Trading Symbol

OPCH

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration